关注风险期外恶心呕吐,优化CINV全程管理  

Focusing on the Nausea and Vomiting beyond Risk Period Contributes to OptimizingCINV Full-Course Management

作　　者：万于茗 朱江 Wan Yuming;Zhu Jiang(Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China;Department of Medical Oncology,Shangjin Nanfu Hospital,West China Hospital,Chengdu 611731,Sichuan,China;Department of Thoracic Oncology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China)

机构地区：[1]四川大学华西医院肿瘤中心,成都610041 [2]上锦南府医院肿瘤科,成都611731 [3]四川大学华西医院肿瘤中心胸部肿瘤科,成都610041

出　　处：《肿瘤预防与治疗》2024年第6期455-461,共7页Journal of Cancer Control And Treatment

基　　金：四川省科技厅项目(编号:23ZDYF2835)。

摘　　要：化疗导致的恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)是癌症治疗期间常见的副反应,严重影响患者生活质量和治疗效果。CINV防控已步入规范化治疗的时代,然而,在临床实践中,CINV仍然困扰着肿瘤患者。造成该现状的原因复杂,其中发生在CINV风险期外的持续时间较长的恶心呕吐值得关注。随着临床研究中观察期延长、真实世界数据不断积累,证实风险期外仍有CINV发生,且发生率在30%以上,对患者化疗间期生活质量影响显著。了解风险期外CINV有助于推进CINV的全程管理,优化CINV防控策略,更好地提高癌症患者的生存质量,改善抗肿瘤治疗效果,也为后续CINV研究开辟了新的方向。Chemotherapy-induced nausea and vomiting(CINV)is a common adverse event during cancer treatment.CINV can negatively affect the quality of life and treatment effect of cancer patients.Despite the coming of an era of standard CINV prevention,CINV still plague patients receiving antitumor drugs in clinic.The causes of this situation are complex,the long-lasting nausea and vomiting beyond the risk period should especially be concerned.With the extension of the observation period in clinical studies and the continuous accumulation of real-world data,it has confirmed that CINV factually occurs beyond risk period,and the incidence is more than 30%.CINV beyond risk period also leads to poor quality of life of cancer patients during chemotherapy.Thus,understanding the nausea and vomiting beyond risk period can contribute to promoting the CINV full-course management,optimizing the strategies of CINV prevention and treatment,improving the quality of life of cancer patients and effect of antitumor therapy,and providing new direction for CINV research.

关 键 词：恶心 呕吐 风险期 

分 类 号：R730.53[医药卫生—肿瘤]